Literature DB >> 32712110

4D flow cardiac magnetic resonance in children and adults with congenital heart disease: Clinical experience in a high volume center.

Marc-Antoine Isorni1, Louis Moisson2, Nidal Ben Moussa3, Sébastien Monnot4, Francesca Raimondi5, Régine Roussin6, Angèle Boet7, Isabelle van Aerschot8, Emmanuelle Fournier9, Sarah Cohen10, Meriem Kara11, Sébastien Hascoet12.   

Abstract

BACKGROUND: Cardiac magnetic resonance (CMR) imaging with velocity encoding along all three directions of flow, known as 4DFlow CMR, provides both anatomical and functional information. Few data are available on the usefulness of 4DFlow CMR in everyday practice. Here, our objective was to investigate the usefulness of 4DFlow CMR for assessing congenital heart disease (CHD) in everyday practice.
METHODS: From 2017 to 2019, consecutive patients who underwent 4DFlow CMR were included prospectively at a single high-volume centre. The parameters recommended by an expert's consensus statement for each diagnosis (congenital valvulopathy, septal defect, complex CHD, tetralogy of Fallot, aortic abnormalities) were assessed by two blinded experienced readers. 4DFlow CMRs that provided all recommended parameters were considered successful. Inter-observer and intra-observer agreement were investigated.
RESULTS: We included 187 adults and 60 children covering broad ranges of weight (4.5-142 kg) and age (0.1-67 years). 4DFlow CMR was always the second-line imaging modality, after inconclusive echocardiography, and was successful in 231/247 (91%) patients, with no significant difference between children and adults (54/60, 90%; and 177/187, 95%; respectively; p = .13). Longer time using 4DFlow CMR at our centre was associated with success; in children, older age was also associated with exam success. There was an about 12-month learning curve in children. The success rate was lowest in neonates. Inter-observer and intra-observer agreement were substantial.
CONCLUSION: Our results suggest that 4DFlow CMR usually provides a comprehensive assessment of CHD in adults and children. A learning curve exists for children and the investigation remains challenging in neonates.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32712110     DOI: 10.1016/j.ijcard.2020.07.021

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Prevalence of Venovenous Shunting and High-Output State Quantified with 4D Flow MRI in Patients with Fontan Circulation.

Authors:  Francesca Raimondi; Duarte Martins; Raluca Coenen; Elena Panaioli; Diala Khraiche; Nathalie Boddaert; Damien Bonnet; Melany Atkins; Howaida El-Said; Laith Alshawabkeh; Albert Hsiao
Journal:  Radiol Cardiothorac Imaging       Date:  2021-12-16

Review 2.  Performance of Cardiac MRI in Pediatric and Adult Patients with Fontan Circulation.

Authors:  Filippo Puricelli; Inga Voges; Peter Gatehouse; Michael Rigby; Cemil Izgi; Dudley J Pennell; Sylvia Krupickova
Journal:  Radiol Cardiothorac Imaging       Date:  2022-06-02

Review 3.  4D Flow MRI in the portal venous system: imaging and analysis methods, and clinical applications.

Authors:  Ryota Hyodo; Yasuo Takehara; Shinji Naganawa
Journal:  Radiol Med       Date:  2022-09-19       Impact factor: 6.313

4.  Segmentation of the Aorta and Pulmonary Arteries Based on 4D Flow MRI in the Pediatric Setting Using Fully Automated Multi-Site, Multi-Vendor, and Multi-Label Dense U-Net.

Authors:  Takashi Fujiwara; Haben Berhane; Michael B Scott; Erin K Englund; Michal Schäfer; Brian Fonseca; Alexander Berthusen; Joshua D Robinson; Cynthia K Rigsby; Lorna P Browne; Michael Markl; Alex J Barker
Journal:  J Magn Reson Imaging       Date:  2021-11-18       Impact factor: 5.119

5.  Novel TrueVue series of 3D echocardiography: Revealing the pathological morphology of congenital heart disease.

Authors:  Feifei Sun; Aijiao Sun; Yixin Chen; Yangjie Xiao; Xintong Zhang; Wei Qiao; Xueying Tan; Yanxiao Liang; Dongyu Li; Shu Yang; Weidong Ren
Journal:  Front Physiol       Date:  2022-09-06       Impact factor: 4.755

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.